Comparative Pharmacology
Head-to-head clinical analysis: PIRMELLA 7 7 7 versus TRI LEGEST 21.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PIRMELLA 7 7 7 versus TRI LEGEST 21.
PIRMELLA 7/7/7 vs TRI-LEGEST 21
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
Combination estrogen-progestin contraceptive; suppresses gonadotropins (FSH, LH), inhibits ovulation, alters cervical mucus and endometrium.
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
One tablet orally once daily for 21 days, followed by 7 tablet-free days. Each tablet contains norgestimate 0.18 mg/ethinyl estradiol 0.025 mg (days 1-7), norgestimate 0.215 mg/ethinyl estradiol 0.025 mg (days 8-14), norgestimate 0.25 mg/ethinyl estradiol 0.025 mg (days 15-21).
None Documented
None Documented
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Ethinyl estradiol: 13-27 hours (mean ~17 hours); norgestimate active metabolite (norelgestromin): 22-36 hours (mean ~28 hours). Steady-state achieved within 5-10 days.
Renal: 70% unchanged; fecal: 30% as metabolites.
Renal: approximately 50-60% as metabolites; fecal: approximately 40-50% (ethinyl estradiol and norgestimate metabolites excreted in bile and feces); less than 1% unchanged in urine.
Category C
Category C
Oral Contraceptive
Oral Contraceptive